Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Jul 28, 2015 10:26am

749 Views

Post# 23966762

Have to be honest!

I have sold half my position since I owned it at an average of a little over five. I'm riding free and clear with my original investment plus some gain. My reason for selling are two. Im very disappointed that Direct II is taking so long. Actually silly me when Linda gave a presentation last September I expected it to start around Thanksgiving. Now we are at August and still no news. Second I don't believe that Germany is offering enough for compensation so the company will not lock themselves in at a low price. Which in effect makes the program a bust in my opinion. Will hold my remaining shares tightly, but do not expect much price movement until fall. Good Luck Everyone! I will be glad if I'm wrong!

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?